Chemren Bio-Engineering Co., Ltd.

Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue.
IC50 Value:
Target: GHSR
Ibutamoren mesylate (MK-0677)  stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor. MK-677is a drug which acts as a potent, orally active growth hormone secretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels. It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. Ibutamoren mesylate (MK-0677)  also alters metabolism of body fat and so may have application in the treatment of obesity.

[1]. Codner, Ethel et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clinical Pharmacology & Therapeutics (St. Louis, MO, United States) (2001), 70(1), 91-98.
 

[2]. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA.MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. Epub 2010 Nov 9.
 

[3]. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group.Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.Neurology. 2008 Nov 18;71(21):1702-8.
 

[4]. Bennett KA, Langmead CJ, Wise A, Milligan G.Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor.Mol Pharmacol. 2009 Oct;76(4):802-11. Epub 2009 Jul 22.
 

[5]. Smith RG, Sun Y, Jiang H, Albarran-Zeckler R, Timchenko N.Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging.Ann N Y Acad Sci. 2007 Nov;1119:147-64.